MedTrace Logo

Impact of Blood-Flow-Restriction Prehabilitation on Pre- and Postoperative Rehabilitation After Total Knee Arthroplasty

NCT06964022 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-05-09

No results posted yet for this study

Summary

Degenerative and traumatic diseases of the musculoskeletal system lead to increased immobility of a patient, which in turn results in muscle atrophy. BFR training is a training method in which a blood pressure cuff partially blocks the arterial blood flow to the exercising limb and completely blocks the venous blood flow. During exercise, an externally induced venous occlusion occurs. This stimulus increases the metabolic stimulus in the occluded extremity - this means that strength can be increased even with low weights, which is why this training is also suitable for people who should not use high training loads due to injuries or operations.

Conditions

  • Osteoarthritis (OA) of the Knee

Interventions

OTHER

Sham-BFR

Six-week prehabilitation program (2/week): Unilateral Leg Press and Leg extension exercise with 30% of the individual 1RM by using a sham-BFR intervention with 20mmHg exercise pressure.

OTHER

BFR

Six-week prehabilitation program (2/week): Unilateral Leg Press and Leg extension exercise with 30% of the individual 1RM by using a BFR intervention with an exercise pressure corresponding to 60% of the individual LOP.

Sponsors & Collaborators

  • University Hospital, Bonn

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-01
Primary Completion
2024-12-31
Completion
2025-02-01

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06964022 on ClinicalTrials.gov